Proteomics and pancreatic cystic neoplasms: a pilot study
| ISRCTN | ISRCTN10626053 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN10626053 |
| Protocol serial number | 001 |
| Sponsor | Geneva University Hospital (Switzerland) |
| Funder | Geneva University Hospital (Switzerland) |
- Submission date
- 03/06/2010
- Registration date
- 10/06/2010
- Last edited
- 10/06/2010
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Digestive System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Jean Louis Frossard
Scientific
Scientific
Service of Gastroenterology
Dept of Internal Medicine
Rue Micheli du Crest
Geneva
1211
Switzerland
Study information
| Primary study design | Observational |
|---|---|
| Study design | Prospective cohort proteomic analysis study |
| Secondary study design | Cohort study |
| Study type | Participant information sheet |
| Scientific title | Use of proteomics to differentiate between benign and potentially malignant pancreatic cystic neoplasms: a pilot study |
| Study objectives | We postulate that a proteomic analysis of pancreatic cystic fluid from patients having a pancreatic cystic neoplasms would be more performant than any other technique to discriminate between benign and malignant lesions. |
| Ethics approval(s) | Ethic Committee of Hirslanden Clinic (Surgery Section), Bern approved in March 2009 |
| Health condition(s) or problem(s) studied | Pancreatic disease |
| Intervention | Prospective collection of pancreatic cystic fluid in patients undergoing open pancreatic surgery aimed at removing the cystic neoplams. Cystic fluid samples collected by direct puncture and submitted to proteomic analysis. |
| Intervention type | Other |
| Primary outcome measure(s) |
To help find specific protein markers to better differentiate between benign and potentially malignant pancreatic cystic neoplams |
| Key secondary outcome measure(s) |
To correlate results of the proteomic analysis to pancreatic histologic staining of surgical samples |
| Completion date | 31/12/2010 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | All |
| Target sample size at registration | 10 |
| Key inclusion criteria | 1. Patients with pancreatic cystic neoplasms as demonstrated by CT scan planned for open surgery 2. Each patient gave his/her informed consent before surgery |
| Key exclusion criteria | 1. Age < 18 years old 2. Pregnant women |
| Date of first enrolment | 01/06/2009 |
| Date of final enrolment | 31/12/2010 |
Locations
Countries of recruitment
- Switzerland
Study participating centre
Service of Gastroenterology
Geneva
1211
Switzerland
1211
Switzerland
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
| Study website | Study website | 11/11/2025 | 11/11/2025 | No | Yes |
